Maruhashi, Tatsuya Hiroshima University
Higashi, Yukihito Hiroshima University
Kihara, Yasuki Hiroshima University
Yamada, Hirotsugu Tokushima University Tokushima University Educator and Researcher Directory KAKEN Search Researchers
Sata, Masataka Tokushima University Tokushima University Educator and Researcher Directory KAKEN Search Researchers
Ueda, Shinichiro University of the Ryukyus
Odawara, Masato Tokyo Medical University
Terauchi, Yasuo Yokohama City University
Dai, Kazuoki Hiroshima City Hospital
Ohno, Jun Tsushima Municipal Hospital
Iida, Masato Mitsubishi Nagoya Hospital
Sano, Hiroaki Nagoya Ekisaikai Hospital
Tomiyama, Hirofumi Tokyo Medical University
Inoue, Teruo Dokkyo Medical University
Tanaka, Atsushi Saga University
Murohara, Toyoaki Nagoya University
Node, Koichi Saga University
Dipeptidyl peptidase 4 inhibitor
Type 2 diabetes
Background: As a sub-analysis of the PROLOGUE study, we evaluated the long-term effect of sitagliptin, a dipeptidyl peptidase 4 inhibitor, on endothelial function in the conduit brachial artery in patients with type 2 diabetes.
Methods: In the PROLOGUE study, patients were randomly assigned to either add-on sitagliptin treatment (sitagliptin group) or continued conventional antihyperglycemic treatment (conventional group). Among the 463 participants in the PROLOGUE study, FMD was measured in 17 patients in the sitagliptin group and 18 patients in the conventional group at the beginning and after 12 and 24 months of treatment.
Results: HbA1c levels were significantly decreased after 12 and 24 months of treatment compared to baseline values in both groups (7.0 ± 0.4 vs. 6.6 ± 0.3 and 6.6 ± 0.4 % in the sitagliptin group; 7.0 ± 0.6 vs. 6.6 ± 0.7 and 6.6 ± 0.7 % in the conventional group; P < 0.05, respectively). There was no significant difference between FMD values at baseline and after 12 and 24 months in the sitagliptin group (4.3 ± 2.6 vs. 4.4 ± 2.1 and 4.4 ± 2.3 %, P = 1.0, respectively). Although FMD had a tendency to increase from 4.3 ± 2.4 % at baseline to 5.2 ± 1.9 % after 12 months and 5.1 ± 2.2 % after 24 months in the conventional group, there was no significant difference between FMD values at baseline and after 12 and 24 months (P = 0.36 and 0.33, respectively).
Conclusions: Add-on sitagliptin to conventional antihyperglycemic drugs in patients with type 2 diabetes did not alter endothelial function in the conduit brachial artery measured by FMD during a 2-year study period. Sitagliptin may be used without concern for an adverse effect on endothelial function in patients with type 2 diabetes.
Springer Nature|BioMed Central
© 2016 The Author(s). This article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
|DOI (Published Version)|
|URL ( Publisher's Version )|
cardiab_15_134.pdf 853 KB